TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17223424

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) alone
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with implantable cardioverter-defibrillator (ICD) backup
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Control group (CRT alone)
Number of subjects: 1303
Study: 14761173

Group type: EXPERIMENTAL
Intervention: Fissure sealant program
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 11495397

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 40 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 41
Study: 9385472

Group type: EXPERIMENTAL
Intervention: Alpha 1-blockade (5 mg prazosin in preceding 24 h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alpha 1-blockade
Number of subjects: 24
Study: 7955188

Group type: EXPERIMENTAL
Intervention: Upper limit of vulnerability tested with two shocks on the peak or the up‐slope of the T wave (protocol 1)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Upper limit of vulnerability tested with three shocks delivered at 0, 20, and 40 milliseconds before the peak of the T wave (protocol 2)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Upper limit of vulnerability in 45 of the 60 patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Upper limit of vulnerability in 51 of the 60 patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Upper limit of vulnerability > 15 J
Number of subjects: 77
Study: 3322532

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (40 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High dose aspirin (324 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (resting state and pacing stress)
Number of subjects: 7
Study: 30919083

Group type: EXPERIMENTAL
Intervention: Fried food consumption 1-3 times/week
Number of subjects: 18941

Group type: EXPERIMENTAL
Intervention: Fried food consumption ≥ 4 times/week
Number of subjects: 18941

Group type: COMPARATOR
Intervention: Fried food consumption < 1 time/week (reference group)
Number of subjects: 18941
Study: 29386371

Group type: EXPERIMENTAL
Intervention: Cool Runnings app-based hot beverage scald prevention campaign
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: First aid training in the past year
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 498
Study: 28638026

Group type: EXPERIMENTAL
Intervention: Su Jok
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study: 26320402

Group type: EXPERIMENTAL
Intervention: Tiotropium + olodaterol 5/5 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium + olodaterol 2.5/5 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium 5 μg
Number of subjects: 0
Study: 23837770

Group type: EXPERIMENTAL
Intervention: Gambling cues exposure
Number of subjects: 250

Group type: COMPARATOR
Intervention: Non-gambling cues exposure
Number of subjects: 250
Study: 21652735

Group type: EXPERIMENTAL
Intervention: varenicline (2 mg/day)
Number of subjects: 218

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 218
Study: 19210040

Group type: EXPERIMENTAL
Intervention: Recreational use of cocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cocaine-free matched sample
Number of subjects: 0
Study: 16963680

Group type: EXPERIMENTAL
Intervention: BPV-S/T
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BPV-S/T-AVAPS
Number of subjects: 10
Study: 12560149

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg per day for 3 days)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cefaclor (40 mg/kg per day for 10 days)
Number of subjects: 78
Study: 11099319

Group type: COMPARATOR
Intervention: 70 Gy external-beam radiotherapy
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: 78 Gy external-beam radiotherapy
Number of subjects: 305

Group type: COMPARATOR
Intervention: 70 Gy external-beam radiotherapy and 78 Gy external-beam radiotherapy
Number of subjects: 305
Study: 8816674

Group type: EXPERIMENTAL
Intervention: Self-directed work team structure
Number of subjects: 0
Study: 1349376

Group type: EXPERIMENTAL
Intervention: Enzyme‐potentiated desensitisation (EPD) - three doses of EPD (beta‐glucuronidase and small quantities of food antigens) intradermally at two‐monthly intervals.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (buffer only)
Number of subjects: 40
Study: 3926254

Group type: EXPERIMENTAL
Intervention: 30% fat parenteral diet
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0% fat parenteral diet
Number of subjects: 41

Group type: COMPARATOR
Intervention: 50% fat parenteral diet
Number of subjects: 41
Study: 30745388

Group type: EXPERIMENTAL
Intervention: 400 mg albendazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg/kg oxantel pamoate
Number of subjects: 0

Group type: COMPARATOR
Intervention: DBS and wet samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitra microsampling device
Number of subjects: 0
Study: 30325931

Group type: EXPERIMENTAL
Intervention: Web-based device-specific videos
Number of subjects: 159

Group type: COMPARATOR
Intervention: Standard personal instruction
Number of subjects: 159
Study: 27108892

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 39
Study: 24658367

Group type: EXPERIMENTAL
Intervention: Client-centred therapy
Number of subjects: 269
Study: 23018695

Group type: EXPERIMENTAL
Intervention: Prineo Skin Closure System
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intraderma sutures
Number of subjects: 83
Study: 20414546

Group type: EXPERIMENTAL
Intervention: 1.8 g/day of L-carnitine for 30 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for 30 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) under resting conditions
Number of subjects: 21
Study: 18341600

Group type: EXPERIMENTAL
Intervention: 0.02% CHX solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 18
Study: 15817862

Group type: EXPERIMENTAL
Intervention: High-sodium diet (3.86 g/d sodium)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-sodium diet (1.30 g/d sodium)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Calcium retention in black girls
Number of subjects: 35
Study: 12430737

Group type: COMPARATOR
Intervention: UVB only
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: UVB combined with vitamin B12 and folic acid
Number of subjects: 27
Study: 11065040

Group type: EXPERIMENTAL
Intervention: Once-weekly drug-in-adhesive (DIA) patches
Number of subjects: 35

Group type: COMPARATOR
Intervention: Reservoir patch
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transdermal patches
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transdermal treatment
Number of subjects: 35
Study: 8871900

Group type: EXPERIMENTAL
Intervention: PWV and heart rate variability indices in patients with diabetic neuropathy
Number of subjects: 227

Group type: COMPARATOR
Intervention: PWV and heart rate variability indices in healthy subjects
Number of subjects: 227
Study: 1361795

Group type: EXPERIMENTAL
Intervention: Intraperitoneal imipenem/cilastatin (2 gm daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intraperitoneal netilmicin and vancomycin (500 and 60-100 mg daily respectively)
Number of subjects: 41
Study: 6235604

Group type: EXPERIMENTAL
Intervention: Impromidine with mepyramine maleate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Impromidine without mepyramine maleate
Number of subjects: 0
Study: 31679521

Group type: EXPERIMENTAL
Intervention: Prolotherapy (4 sessions, monthly intervals)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physiotherapy (weekly for 4 sessions)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined (prolotherapy + physiotherapy)
Number of subjects: 120
Study: 30309995

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil for 12 weeks
Number of subjects: 340

Group type: COMPARATOR
Intervention: Prednisone for 12 weeks
Number of subjects: 340
Study: 27220527

Group type: EXPERIMENTAL
Intervention: Manual Therapy + Kinesio Taping + Exercise (MT + KT + EX)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy + Manual Therapy + Kinesio Taping + Exercise (HILT + MT + KT + EX)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Kinesio Taping + Exercise (KT + EX)
Number of subjects: 70
Study: 24554030

Group type: EXPERIMENTAL
Intervention: StomaphyX treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 120
Study: 22179130

Group type: EXPERIMENTAL
Intervention: Pinitol (1,200 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 20483969

Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Supportive therapy and education (Control)
Number of subjects: 126
Study: 17715209

Group type: EXPERIMENTAL
Intervention: Tyrosine-depleting amino acid mixture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Balanced amino acid mixture
Number of subjects: 100
Study: 15508014

Group type: EXPERIMENTAL
Intervention: LKFibre diet
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 38
Study: 11526558

Group type: EXPERIMENTAL
Intervention: Bupivacaine alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Morphine alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Morphine mixed with bupivacaine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (Sterile saline solution)
Number of subjects: 32
Study: 9126192

Group type: EXPERIMENTAL
Intervention: 30 or 60 mg/kg ALA preoperatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dose of ALA (60 mg/kg)
Number of subjects: 0
Study: 8290743

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg b.d. for 4 days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg o.d. for 4 days
Number of subjects: 34
Study: 3306159

Group type: EXPERIMENTAL
Intervention: Chemotherapy (BCNU 80 mg/M2 I.V. every 4 weeks, actinomycin‐D 0.01 mg/kg, and vincristine 1.0 mg/M2 I.V. every 2 weeks for 6 months)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Surgical control
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 59
Study: 2769192

Group type: EXPERIMENTAL
Intervention: Microcomputer tickler system
Number of subjects: 1262

Group type: COMPARATOR
Intervention: No information regarding previous mammograms printed
Number of subjects: 1262
Study: 5555492

Group type: EXPERIMENTAL
Intervention: Asymptomatic bacteriuria during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maternal urinary infection
Number of subjects: 0
Study: 30895296

Group type: EXPERIMENTAL
Intervention: Early goal-directed haemodynamic optimization (EGDHO) with MAP 85-100 mmHg
Number of subjects: 112

Group type: COMPARATOR
Intervention: MAP 65 mmHg strategy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Early goal-directed haemodynamic optimization (EGDHO)
Number of subjects: 112
Study: 27650995

Group type: EXPERIMENTAL
Intervention: Spironolactone (50mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRD
Number of subjects: 24
Study: 26066299

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid (FA) supplementation for 3 months
Number of subjects: 0
Study: 24140390

Group type: EXPERIMENTAL
Intervention: Bivalent killed whole-cell oral cholera vaccine (two doses, 14 days apart)
Number of subjects: 34968

Group type: COMPARATOR
Intervention: Heat-killed Escherichia coli K12 placebo
Number of subjects: 34968
Study: 21641352

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 4133
Study: 19030772

Group type: EXPERIMENTAL
Intervention: Insulin glargine (at dinnertime)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH) insulin (at bedtime)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus OADs
Number of subjects: 20

Group type: COMPARATOR
Intervention: NPH plus OADs
Number of subjects: 20
Study: 16844265

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restriction
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Protein-restriction
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (no restriction)
Number of subjects: 3
Study: 15564113

Group type: EXPERIMENTAL
Intervention: Multilayer perceptron neural network (MLPNN) trained with Lyapunov exponents as inputs
Number of subjects: 0
Study: 11520523

Group type: EXPERIMENTAL
Intervention: Cardiotocography plus ST analysis (CTG+ST group)
Number of subjects: 4966

Group type: COMPARATOR
Intervention: Cardiotocography only (CTG group)
Number of subjects: 4966
Study: 9118711

Group type: EXPERIMENTAL
Intervention: Inhaled cocaine base (45 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV cocaine HCl (0.35 to 0.50 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled placebo (4.5 mg cocaine base)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IV placebo (saline solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaine (inhaled or IV)
Number of subjects: 0
Study: 7505979

Group type: EXPERIMENTAL
Intervention: Serum PSA value of 10 ng/mL or less
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staging radionuclide bone scan
Number of subjects: 0
Study: 2941208

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of sodium chloride/potassium chloride solution (saline) 6 ml/kg body weight
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of sodium chloride/potassium chloride solution (saline) 12 ml/kg body weight
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of sodium chloride/potassium chloride solution (saline) 18 ml/kg body weight
Number of subjects: 7
Study: 29135589

Group type: EXPERIMENTAL
Intervention: Tao mask
Number of subjects: 152
Study: 26018213

Group type: EXPERIMENTAL
Intervention: Epidural
Number of subjects: 17

Group type: COMPARATOR
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 17
Study: 25010300

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral vaporization of the prostate (TUVP)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate (TURP)
Number of subjects: 88
Study: 22159015

Group type: EXPERIMENTAL
Intervention: Eyes with POAG (n = 359)
Number of subjects: 2609

Group type: COMPARATOR
Intervention: Non-POAG eyes (n = 2250)
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Eyes reaching POAG endpoints based on only VF change (n = 74)
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Eyes reaching POAG endpoints based on only optic disc change (n = 158)
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: Eyes reaching POAG endpoints for both VF and optic disc change (n = 127)
Number of subjects: 2609

Group type: COMPARATOR
Intervention: Original OHTS randomization (observe vs. treat)
Number of subjects: 2609
Study: 20035818

Group type: EXPERIMENTAL
Intervention: Silybum marianum extract (600 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Fluoxetine (30 mg/day)
Number of subjects: 35
Study: 18810506

Group type: EXPERIMENTAL
Intervention: Adenosine 5′-triphosphate (ATP) infusions, maximum of eight weekly intravenous 8-10 h infusions
Number of subjects: 51
Study: 16407509

Group type: EXPERIMENTAL
Intervention: Aerosol cyclosporine (300 mg, three days a week for two years)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Aerosol placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Aerosol cyclosporine
Number of subjects: 58
Study: 12823382

Group type: EXPERIMENTAL
Intervention: Infra-diaphragmatic irradiation
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Infra- and supra-diaphragmatic irradiation
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 487
Study: 10789574

Group type: EXPERIMENTAL
Intervention: 2% glutaraldehyde
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ethylene oxide
Number of subjects: 40
Study: 9200379

Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 436

Group type: COMPARATOR
Intervention: Seroreverters (uninfected infants of HIV-1-infected mothers)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Seronegative infants (uninfected infants born to HIV-negative mothers)
Number of subjects: 436
Study: 8307542

Group type: EXPERIMENTAL
Intervention: Tetrazepam (150 mg or a lower dose from the third day onward)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tetrazepam
Number of subjects: 20
Study: 3327362

Group type: EXPERIMENTAL
Intervention: Adenosine (up to 120 micrograms kg‐1 min‐1) after saline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adenosine after propranolol (0.2 mg kg‐1 body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol plus atropine (0.2 mg kg‐1 plus 0.04 mg kg‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adenosine compared with saline on standing
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adenosine during Valsalva manoeuvre
Number of subjects: 6
Study: 30957838

Group type: EXPERIMENTAL
Intervention: TeraPCA software for Principal Component Analysis
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Current state-of-the-art software for Principal Component Analysis
Number of subjects: 1000000
Study: 28062271

Group type: EXPERIMENTAL
Intervention: Financial Incentives
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Social Goals
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study: 26163311

Group type: EXPERIMENTAL
Intervention: Preferred music during surgical closure
Number of subjects: 0
Study: 24319955

Group type: EXPERIMENTAL
Intervention: Pegasys (pegylated interferon alpha‐2a) for 48 weeks
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (ALT > 2 x ULN)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study: 21226787

Group type: EXPERIMENTAL
Intervention: Medical screening + access to a website and coaching
Number of subjects: 287

Group type: COMPARATOR
Intervention: Usual care (medical screening only)
Number of subjects: 287
Study: 17697788

Group type: EXPERIMENTAL
Intervention: Perceptual fluency based on speed of processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective experience of fluency
Number of subjects: 0
Study: 16517329

Group type: EXPERIMENTAL
Intervention: 150 mg of 3% chloroprocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 13129737

Group type: EXPERIMENTAL
Intervention: Losartan therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: No losartan therapy (Control)
Number of subjects: 45
Study: 11204662

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (Eloxatin) in preoperative combined‐modality treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care with radiation and fluorouracil (5‐FU)‐based chemotherapy
Number of subjects: 0
Study: 8869673

Group type: EXPERIMENTAL
Intervention: Desflurane (1.3 MAC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Isoflurane (1.3 MAC)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Desflurane and Isoflurane (both groups)
Number of subjects: 41
Study: 1497152

Group type: EXPERIMENTAL
Intervention: Interpretation of radiographs of both the injured and uninjured elbow
Number of subjects: 25

Group type: COMPARATOR
Intervention: Interpretation of radiographs of the injured elbow only
Number of subjects: 25
Study: 6475561

Group type: EXPERIMENTAL
Intervention: Iohexol 350 mg I/ml (Omnipaque)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Meglumine, Na‐Ca‐metrizoate 370 mg I/ml (Isopaque Coronar)
Number of subjects: 30
Study: 30468530

Group type: EXPERIMENTAL
Intervention: High dose UVA1 (130 J/cm2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Medium dose UVA1 (60 J/cm2)
Number of subjects: 27
Study: 29424239

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (lixisenatide, liraglutide, semaglutide, exenatide)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (liraglutide)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (semaglutide)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (exenatide)
Number of subjects: 4

Group type: COMPARATOR
Intervention: GLP-1 receptor agonists
Number of subjects: 4
Study: 26224021

Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF) with maternity vouchers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBF with management authority within a health district
Number of subjects: 0
Study: 24470641

Group type: EXPERIMENTAL
Intervention: Closed-loop automatic control (CLAC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Routine manual control (RMC)
Number of subjects: 34
Study: 22717961

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (PDS plus®)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Uncoated sutures (PDS II®)
Number of subjects: 485
Study: 19631869

Group type: EXPERIMENTAL
Intervention: Aortic Aneurysm Repair (AAR)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carotid Revascularization (CR)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lower Extremity Revascularization (LER)
Number of subjects: 52
Study: 17440207

Group type: EXPERIMENTAL
Intervention: Intermediate number of linguistic cues in analogies
Number of subjects: 0

Group type: COMPARATOR
Intervention: High cue frequency versions of analogies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low cue frequency versions of analogies
Number of subjects: 0
Study: 15077083

Group type: EXPERIMENTAL
Intervention: Primary PCI for AMI
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Absent ST-segment resolution (STR) after PCI
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 695
Study: 12530280

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (single oral dose)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98